文献速递头颈外科咽喉与嗓音

头颈癌患者腭咽功能障碍的识别

Identifying Velopharyngeal Dysfunction in Head and Neck Cancer Patients.
PubMed 文献 · Laryngoscope · 2026-08-18

本研究通过电子查询和人工病历回顾,在三个三级中心识别头颈癌治疗后出现腭咽功能障碍(VPD)相关症状的患者,分析临床特征与风险因素。共纳入142例患者,最常见的原发肿瘤部位为口咽和口腔。晚期疾病(T3-T4)与鼻反流相关,较高放疗剂量与内镜下VPD可能性增加相关且呈剂量反应关系,但该关联未见于临床结局。VPD发病潜伏期因治疗方式而异,手术后的潜伏期较短,放疗后的潜伏期较长。言语语言病理学(SLP)评估常见,但标准化症状结局指标和仪器评估在各机构间不一致且使用不足。结论认为VPD是头颈癌治疗中未被充分认识的后遗症,可能与原发肿瘤部位、晚期疾病和放疗剂量相关。

要点

  • 晚期(T3-T4)头颈癌与鼻反流相关。
  • 较高放疗剂量与内镜下VPD可能性增加相关,呈剂量反应关系。
  • VPD潜伏期因治疗方式不同:手术后较短,放疗后较长。

核心结论

  • VPD是头颈癌治疗中未被充分认识的后遗症,可能与原发肿瘤部位、晚期疾病和放疗剂量相关。
  • 治疗方式影响VPD诊断的潜伏期。
  • SLP评估和结局测量的变异性强调需要更标准化的评估方法。

研究设计与样本

  • 通过电子查询和人工病历回顾,在三个三级中心识别头颈癌及后续VPD相关症状的患者。
  • 收集人口学、肿瘤学和处理变量,包括肿瘤亚部位、T分期、治疗方式和放疗剂量。
  • 共142例患者符合纳入标准。

主要发现

  • 本队列中最常见的原发肿瘤亚部位为口咽和口腔。
  • 晚期疾病(T3-T4)比早期疾病(Tis-T2)更常见,并与鼻反流相关。
  • 较高放疗剂量与内镜下VPD可能性增加相关,呈剂量反应关系;但该关联未见于临床结局。
  • VPD发病潜伏期因治疗方式而异,手术后较短,放疗后较长。
  • SLP评估常见,但标准化症状结局指标和仪器评估在各机构间不一致且使用不足。

临床怎么用

  • 对头颈癌治疗后患者应警惕VPD,尤其晚期疾病和接受较高放疗剂量者。
  • 不同治疗方式下VPD潜伏期不同,随访中需注意时间差异。
  • 建议采用标准化症状结局指标和仪器评估以提高VPD识别和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To characterize the clinical features and risk factors associated with velopharyngeal dysfunction (VPD) following head and neck cancer (HNC) treatment. METHODS: Patients with HNC and subsequent VPD-related symptoms were identified through electronic query and manual chart review across three tertiary centers. Demographic, oncologic, and treatment variables, including tumor subsite, T stage, treatment modality, and radiation dose, were collected. VPD-related outcomes included hypernasality, nasal regurgitation, reduced intelligibility, and evidence of velopharyngeal insufficiency on endoscopy. Associations were evaluated using univariate tests and logistic regression, with radiation dose modeled as a continuous variable. RESULTS: A total of 142 patients met inclusion criteria. The most common primary tumor subsites in this cohort were oropharyngeal and oral cavity. Advanced-stage disease (T3-T4) was more common than early-stage disease (Tis-T2) and was associated with nasal regurgitation. Higher radiation dose was associated with increased likelihood of endoscopic VPD, with a dose-response relationship observed; however, this association was not observed for clinical outcomes. Latency to VPD onset varied by treatment modality, with shorter latency following surgery and longer latency following radiation-based therapies. Speech-language pathology (SLP) evaluation was commonly performed; however, standardized symptom outcome metrics and instrumental assessments were inconsistent and underutilized across institutions. CONCLUSION: VPD is an underrecognized sequela of HNC treatment, and may be associated with primary tumor subsite, advanced disease, and radiation dose. Treatment modality contributes to latency in VPD diagnosis. Variability in SLP evaluation and outcome measurement highlights the need for more standardized assessment approaches to improve identification and management of VPD in this population.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Newman K, Neevel A, Hess H, et al. Identifying Velopharyngeal Dysfunction in Head and Neck Cancer Patients. Laryngoscope. 2026. PMID: 42610749. doi:10.1002/lary.70792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。